Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Humacyte Inc has a consensus price target of $13.13 based on the ratings of 9 analysts. The high is $25 issued by D. Boral Capital on March 7, 2025. The low is $3 issued by Piper Sandler on November 10, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., D. Boral Capital, and D. Boral Capital on March 12, 2025, March 7, 2025, and February 27, 2025, respectively. With an average price target of $21.67 between HC Wainwright & Co., D. Boral Capital, and D. Boral Capital, there's an implied 829.90% upside for Humacyte Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/12/2025 | Buy Now | 543.78% | HC Wainwright & Co. | Vernon Bernardino52% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
03/07/2025 | Buy Now | 972.96% | D. Boral Capital | Jason Kolbert48% | $25 → $25 | Maintains | Buy | Get Alert |
02/27/2025 | Buy Now | — | Benchmark | Bruce Jackson42% | — | Reiterates | Buy → Buy | Get Alert |
02/27/2025 | Buy Now | 972.96% | D. Boral Capital | Jason Kolbert48% | $25 → $25 | Maintains | Buy | Get Alert |
02/26/2025 | Buy Now | 972.96% | D. Boral Capital | Jason Kolbert48% | $25 → $25 | Maintains | Buy | Get Alert |
01/21/2025 | Buy Now | 972.96% | D. Boral Capital | Jason Kolbert48% | $25 → $25 | Maintains | Buy | Get Alert |
01/13/2025 | Buy Now | 972.96% | D. Boral Capital | Jason Kolbert48% | $25 → $25 | Maintains | Buy | Get Alert |
12/23/2024 | Buy Now | 629.61% | Benchmark | Bruce Jackson42% | $15 → $17 | Maintains | Buy | Get Alert |
12/20/2024 | Buy Now | 972.96% | D. Boral Capital | Jason Kolbert48% | $25 → $25 | Maintains | Buy | Get Alert |
12/20/2024 | Buy Now | 543.78% | HC Wainwright & Co. | Vernon Bernardino52% | $12 → $15 | Reiterates | Buy → Buy | Get Alert |
11/21/2024 | Buy Now | 972.96% | D. Boral Capital | Jason Kolbert48% | $25 → $25 | Maintains | Buy | Get Alert |
11/18/2024 | Buy Now | 415.02% | HC Wainwright & Co. | Vernon Bernardino52% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
11/13/2024 | Buy Now | 415.02% | HC Wainwright & Co. | Vernon Bernardino52% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
11/11/2024 | Buy Now | 972.96% | D. Boral Capital | Jason Kolbert48% | $25 → $25 | Maintains | Buy | Get Alert |
11/05/2024 | Buy Now | 415.02% | HC Wainwright & Co. | Vernon Bernardino52% | $6 → $12 | Maintains | Buy | Get Alert |
10/28/2024 | Buy Now | 972.96% | EF Hutton | Jason Kolbert48% | $25 → $25 | Maintains | Buy | Get Alert |
10/18/2024 | Buy Now | 329.18% | TD Cowen | Joshua Jennings55% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
10/18/2024 | Buy Now | 329.18% | BTIG | Ryan Zimmerman72% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
10/10/2024 | Buy Now | 543.78% | Benchmark | Bruce Jackson42% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
10/01/2024 | Buy Now | 972.96% | EF Hutton | Jason Kolbert48% | $25 → $25 | Maintains | Buy | Get Alert |
09/20/2024 | Buy Now | 457.94% | Cantor Fitzgerald | Kristen Kluska70% | $13 → $13 | Reiterates | Overweight → Overweight | Get Alert |
09/09/2024 | Buy Now | 972.96% | EF Hutton | Jason Kolbert48% | → $25 | Initiates | → Buy | Get Alert |
09/05/2024 | Buy Now | 543.78% | Benchmark | Bruce Jackson42% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
08/14/2024 | Buy Now | 543.78% | Benchmark | Bruce Jackson42% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
08/12/2024 | Buy Now | 543.78% | Benchmark | Bruce Jackson42% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
07/15/2024 | Buy Now | 372.1% | BTIG | Ryan Zimmerman72% | $8 → $11 | Maintains | Buy | Get Alert |
07/02/2024 | Buy Now | 200.43% | Cantor Fitzgerald | Kristen Kluska70% | $7 → $7 | Reiterates | Overweight → Overweight | Get Alert |
07/02/2024 | Buy Now | 543.78% | Benchmark | Bruce Jackson42% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
05/24/2024 | Buy Now | 543.78% | Benchmark | Bruce Jackson42% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
05/13/2024 | Buy Now | 543.78% | Benchmark | Bruce Jackson42% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
04/01/2024 | Buy Now | 200.43% | Cantor Fitzgerald | Kristen Kluska70% | $7 → $7 | Reiterates | Overweight → Overweight | Get Alert |
03/26/2024 | Buy Now | 71.67% | Piper Sandler | Allison Bratzel65% | $4 → $4 | Maintains | Neutral | Get Alert |
03/25/2024 | Buy Now | 543.78% | Benchmark | Bruce Jackson42% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
03/08/2024 | Buy Now | 71.67% | Piper Sandler | Allison Bratzel65% | $3 → $4 | Maintains | Neutral | Get Alert |
12/27/2023 | Buy Now | 543.78% | Benchmark | Bruce Jackson42% | $16 → $15 | Maintains | Buy | Get Alert |
12/11/2023 | Buy Now | 157.51% | HC Wainwright & Co. | Vernon Bernardino52% | → $6 | Initiates | → Buy | Get Alert |
11/10/2023 | Buy Now | 28.76% | Piper Sandler | Matt O'Brien51% | $3.5 → $3 | Maintains | Neutral | Get Alert |
09/21/2023 | Buy Now | 200.43% | Cantor Fitzgerald | Kristen Kluska70% | → $7 | Reiterates | Overweight → Overweight | Get Alert |
08/31/2023 | Buy Now | 157.51% | Cantor Fitzgerald | Kristen Kluska70% | → $6 | Reiterates | Overweight → Overweight | Get Alert |
08/24/2023 | Buy Now | 157.51% | Cantor Fitzgerald | Kristen Kluska70% | → $6 | Reiterates | Overweight → Overweight | Get Alert |
08/15/2023 | Buy Now | 586.7% | Benchmark | Bruce Jackson42% | → $16 | Reiterates | Buy → Buy | Get Alert |
06/22/2023 | Buy Now | 157.51% | Cantor Fitzgerald | Kristen Kluska70% | → $6 | Initiates | → Overweight | Get Alert |
06/12/2023 | Buy Now | 586.7% | Benchmark | Bruce Jackson42% | → $16 | Reiterates | Buy → Buy | Get Alert |
03/27/2023 | Buy Now | 586.7% | Benchmark | Bruce Jackson42% | → $16 | Reiterates | → Buy | Get Alert |
07/18/2022 | Buy Now | 329.18% | BTIG | Ryan Zimmerman72% | $12 → $10 | Maintains | Buy | Get Alert |
The latest price target for Humacyte (NASDAQ:HUMA) was reported by HC Wainwright & Co. on March 12, 2025. The analyst firm set a price target for $15.00 expecting HUMA to rise to within 12 months (a possible 543.78% upside). 31 analyst firms have reported ratings in the last year.
The latest analyst rating for Humacyte (NASDAQ:HUMA) was provided by HC Wainwright & Co., and Humacyte reiterated their buy rating.
There is no last upgrade for Humacyte
There is no last downgrade for Humacyte.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on March 12, 2025 so you should expect the next rating to be made available sometime around March 12, 2026.
While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a reiterated with a price target of $15.00 to $15.00. The current price Humacyte (HUMA) is trading at is $2.33, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.